SCHEMBL935327

SCHEMBL935327

CCCCCCCCCCCCCCCC(=O)C1=C(O)C(C)OC1=O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 7/20 0.71
▸ ACP1 P24666 5/20 0.71
▸ CDC25B P30305 5/20 0.71
▸ MAPT P10636 3/20 0.71
▸ HPSE Q9Y251 2/20 0.71
▸ DUSP3 P51452 2/20 0.71
▸ RECQL P46063 2/20 0.71
▸ TDP1 Q9NUW8 2/20 0.71
▸ PTPN2 P17706 1/20 0.71
▸ MEN1 O00255 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ ATM Q13315 1/20 0.45
▸ HSD17B3 P37058 5/20 0.42
▸ PLA2G2A P14555 2/20 0.42
▸ PLA2G5 P39877 2/20 0.42
▸ HSPD1 P10809 1/20 0.42
▸ HSPE1 P61604 1/20 0.42
▸ TST Q16762 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1030268 0.83 CDC25B (1.00) PTPN1ACP1CDC25BMAPTHPSE
SCHEMBL4403663 0.83 CDC25B (1.00) PTPN1ACP1CDC25BMAPTHPSE
SCHEMBL28550801 0.82 CDC25B (0.97) PTPN1ACP1CDC25BMAPTHPSE
SCHEMBL7963589 0.78 CDC25B (1.00) PTPN1ACP1CDC25BMAPTHPSE
SCHEMBL16433256 0.77 CDC25B (0.85) PTPN1ACP1CDC25BMAPTHPSE
SCHEMBL16431876 0.77 CDC25B (0.85) PTPN1ACP1CDC25BMAPTHPSE
SCHEMBL16432859 0.77 CDC25B (0.85) PTPN1ACP1CDC25BMAPTHPSE
SCHEMBL16431415 0.77 CDC25B (0.85) PTPN1ACP1CDC25BMAPTHPSE
SCHEMBL17356811 0.76 PTPN1 (0.53) PTPN1ACP1CDC25BMAPTHPSE
SCHEMBL17356818 0.76 PTPN1 (0.53) PTPN1ACP1CDC25BMAPTHPSE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9668959-B2 A3 adenosine receptor ligands for modulation of pigmentation ORADIN PHARMACEUTICAL LTD. (IL) 2017-06-06 — — US disclosed
EP-2456419-B1 A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION ORADIN PHARMACEUTICAL LTD (IL) 2016-11-23 — — EP disclosed
US-20160136079-A1 A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION ORADIN PHARMACEUTICAL LTD. (IL) 2016-05-19 — — US disclosed
US-9199102-B2 A3 adenosine receptor ligands for modulation of pigmentation ORADIN PHARMACEUTICAL LTD. (IL) 2015-12-01 — — US disclosed
US-20120134945-A1 A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION ORADIN PHARMACEUTICAL LTD. (IL) 2012-05-31 — — US disclosed
EP-2456419-A1 A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION Oradin Pharmaceutical Ltd. (IL) 2012-05-30 — — EP disclosed
WO-2011010306-A1 A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2011-01-27 — — WO disclosed
US-7019029-B2 Skin whiteners containing hydroxytetronic acid derivatives THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY, AS ADMINISTRATIVE AGENT 2006-03-28 — — US disclosed
US-20020141956-A1 Skin whiteners containing hydroxytetronic acid derivatives THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY, AS ADMINISTRATIVE AGENT 2002-10-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020141956-A1 Skin whiteners containing hydroxytetronic acid derivatives TYR, PPP6C, CYP26A1 PTPN1 77/4885ACP1 49/4885CDC25B 2448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback